Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $4.1 million.

  • Theravance Biopharma's Other Non Operating Income rose 19250.88% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 2773.01%. This contributed to the annual value of $4.9 million for FY2024, which is 4645.68% down from last year.
  • Theravance Biopharma's Other Non Operating Income amounted to $4.1 million in Q3 2025, which was up 19250.88% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Other Non Operating Income peaked at $4.1 million during Q3 2025, and registered a low of -$3.0 million during Q3 2022.
  • Its 5-year average for Other Non Operating Income is $1.3 million, with a median of $1.4 million in 2024.
  • Over the last 5 years, Theravance Biopharma's Other Non Operating Income had its largest YoY gain of 100118.34% in 2022, and its largest YoY loss of 172771.08% in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's Other Non Operating Income stood at $338000.0 in 2021, then skyrocketed by 1001.18% to $3.7 million in 2022, then crashed by 50.38% to $1.8 million in 2023, then plummeted by 51.06% to $904000.0 in 2024, then surged by 357.85% to $4.1 million in 2025.
  • Its Other Non Operating Income stands at $4.1 million for Q3 2025, versus $1.5 million for Q2 2025 and $939000.0 for Q1 2025.